Standing Committee Report Summary
The Drugs and Cosmetics (Amendment) Bill, 2007

- The Committee feels that the physiological and therapeutic impact of drugs and cosmetics on human bodies is completely different. Therefore, trials for drugs should be separate from that of cosmetics. The Committee thus recommends that there should be a separate set of provisions for clinical trials for regulating the dermatological safety of cosmetics. The Committee also suggests that a separate definition of clinical trial for medical devices may be included in the Bill. The Committee also feels that only new drugs should be subjected to clinical trials.
- The Committee strongly recommends that a dedicated division (as per Mashelkar Committee report) may be set up to deal with regulation, licensing, surveillance and monitoring of medical devices. The definition of medical devices should also be brought in line with the definition of Global Harmonisation Task Force.
- The Mashelkar Committee had recommended that the existing Central Drugs Standard and Control Organisation (CDSCO) be strengthened and equipped properly rather than creating a new authority. The Committee, thus, recommends that the CDSCO be strengthened and restructured as a Central Drug Administration, which shall be an independent body under the Ministry of Health and Family Welfare.
- The Mashelkar Committee had drawn a roadmap for centralisation of licensing in three phases. It had stated that the exercise should be complete within three years. However, the Ministry indicated that it might take five to 10 years to switch to the centralised licensing system. The Committee recommends that the roadmap drawn by the Mashelkar Committee be followed for a speedy switchover.
- The Committee suggests that the appellate authority for grievance redressal should be placed in the zonal and sub-zonal offices of the licensing authority so that small scale pharma units do not face any problems.
- The Committee is of the opinion that the central government would need to put substantive additional funds to strengthen the CDSCO.
- The Committee recommends that the Drugs Technical Advisory Board should be retained since it’s a technical body with representation of experts from various fields whose main function is to advise the government.

DISCLAIMER: This document is being furnished to you for your information. You may choose to reproduce or redistribute this report for non-commercial purposes in part or in full to any other person with due acknowledgement of PRS Legislative Research ("PRS"). The opinions expressed herein are entirely those of the author(s). PRS makes every effort to use reliable and comprehensive information, but PRS does not represent that the contents of the report are accurate or complete. PRS is an independent, not-for-profit group. This document has been prepared without regard to the objectives or opinions of those who may receive it.